Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Michael P Randall, Andreas Rauschecker, Liam Gima-Lange, Jenai Wilmoth, Lingjing Chen, Ming Lu, Huimin Geng, Haifaa Abdulhaq, James L. Rubenstein

Blood (2023) 142 (Supplement 1): 3104.

https://doi.org/10.1182/blood-2023-190698

Published: 2023

Journal Articles

Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020

Abdul Rahman Al Armashi, Anas Al Zubaidi, Omar Mahmood, Marisa Thierheimer, Akram Alkrekshi, Haifaa Abdulhaq

Blood (2023) 142 (Supplement 1): 1765.

https://doi.org/10.1182/blood-2023-180270

Published: 2023

Journal Articles

Disparities in Genetic Profiles, Risk Stratification and Outcomes in Adults with Acute Myeloid Leukemia Comparing Patients of Hispanic and Non-Hispanic Ethnicity in Central California

Omar Mahmood, Tanjot Saini, Daniel Park, Sundeep Bekal, Inderpreet Bal, Simran Saini, Tabark Altai, Yousef Fayed, Yueqi Yan, Haifaa Abdulhaq

Blood (2023) 142 (Supplement 1): 7423.

https://doi.org/10.1182/blood-2023-184600

Published: 2023

Journal Articles

Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups

Elizabeth A. Brem, John M. Burke, Mirko Vukcevic, Pia Kloepfer, Kimberly Saverno, Haifaa Abdulhaq, Andrew M Evens, Pierluigi Porcu, Mazyar Shadman, Christopher R. Flowers

Blood (2023) 142 (Supplement 1): 6251.

https://doi.org/10.1182/blood-2023-188482

Published: 2023

Journal Articles

Optimizing Acute Sickle Cell Care at Community Health Partners Medical Center

Jeffrey T Means, Nicole Palmer, Jeffrey Uller, Daniel Park, Andrew Hwang, Brian Chinnock, Marsha Treadwell, Patrick Macmillan, Haifaa Abdulhaq, Wesley Viau, Nivedana Ravi, Sani Bukari

Blood (2023) 142 (Supplement 1): 7234.

https://doi.org/10.1182/blood-2023-187948

Published: 2023

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators

Fredrik Schjesvold, Heinz Ludwig, María-Victoria Mateos, Haifaa Abdulhaq, Stefan Norin, Marcus Thuresson, Nicolaas A. Bakker, Paul G. Richardson, Pieter Sonneveld

Blood (2022) 140 (Supplement 1): 12607–12609.

https://doi.org/10.1182/blood-2022-160159

Published: 2022

Journal Articles

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Michelle A. Quan, Shiliang Zhang, Daria Gaut, Patricia A. Young, Haifaa Abdulhaq, Kevin Shieh, Jack Reid, Elizabeth A. Brem, Benjamin Heyman, Joseph Tuscano

Blood (2022) 140 (Supplement 1): 4851–4852.

https://doi.org/10.1182/blood-2022-163552

Published: 2022

Journal Articles

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Haifaa Abdulhaq, Omar Mahmood, Calvin Kuan Jung Chen, Azra Borogovac, Matthew Wieduwilt, Anand Annan, Yueqi Yan, Maher Albitar

Blood (2022) 140 (Supplement 1): 3553–3554.

https://doi.org/10.1182/blood-2022-164902

Published: 2022

Journal Articles

Avoiding Daratumumab Interference with Blood Typing

Charity A Huang, Fouad Boulbol, Sundeep Bekal, Seema Policepatil, Haifaa Abdulhaq, Sani Bukari

Blood (2022) 140 (Supplement 1): 13076–13077.

https://doi.org/10.1182/blood-2022-155650

Published: 2022

Journal Articles

Characteristics and Outcomes of Multiple Myeloma in Hispanic Versus Non-Hispanic Patients in Central California

Andrew Hwang, Daniel Park, Jason Doornenbal, Inderpreet Bal, Sani Bukari, Yueqi Yan, Haifaa Abdulhaq

Blood (2022) 140 (Supplement 1): 12568–12569.

https://doi.org/10.1182/blood-2022-168307

Published: 2022

Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano

Blood (2022) 140 (Supplement 1): 11954–11955.

https://doi.org/10.1182/blood-2022-164905

Published: 2022

Journal Articles

Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley

Charity A Huang, Omar Mahmood, Paul Mills, Mehdia Amini, Sundeep Bekal, Jason Doornenbal, Sani Bukari, Yabby Abejie, Haifaa Abdulhaq

Blood (2021) 138 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2021-145608

Published: 2021

Journal Articles

Clinicopathologic Characteristic and Natural History of Patients with Non Hereditary, Non Polycythemia Vera (NH/NPV) Persistent Polycythemia

Omar Mahmood, Hanson Mouanoutoua, Tanjot Saini, Marcel Okura, Mahboub Rahman Noori, Nadia Almasri, Haifaa Abdulhaq, Sani Bukari

Blood (2021) 138 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2021-152098

Published: 2021

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Paul G. Richardson, Fredrik H. Schjesvold, Haifaa Abdulhaq, Daniel Coriu, Antonio Lazzaro, Pieter Sonneveld, Torbjörn Kullenburg, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, María-Victoria Mateos

Blood (2021) 138 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2021-146863

Published: 2021

Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano

Blood (2021) 138 (Supplement 1): 2509.

https://doi.org/10.1182/blood-2021-151374

Published: 2021

Journal Articles

Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin

Tiffany Guan, Mimi Lo, Rebecca Young, Fouad Boulbol, Hanson Mouanoutoua, Raymond Chu, Weiyun Z. Ai, Haifaa Abdulhaq, Bita Fakhri

Blood (2021) 138 (Supplement 1): 2511.

https://doi.org/10.1182/blood-2021-151420

Published: 2021

Journal Articles

Using Targeted RNA Next Generation Sequencing and Differential Expression to Compare Primary Central Nervous System Lymphoma with CD+ DLBCL, Nodal DLBCL and EBV+ DLBCL

Haifaa Abdulhaq, MD, Maher Albitar

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-142235

Published: 2020

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Heather L. Benjamin, MD, James M. Rossetti, DO, Aaron J. Lampkin, MSIV, Christie Hilton, DO, Entezam Sahovic, MD, Haifaa Abdulhaq, Richard K. Shadduck, MD, Namratha Vemulapalli, MD, Amanda Hercules, MD, John Lister, MD

Blood (2009) 114 (22): 4164.

https://doi.org/10.1182/blood.V114.22.4164.4164

Published: 2009

Journal Articles

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia

George Labban, M.D., James M. Rossetti, D.O., Richard K. Shadduck, M.D., Entezam Sahovic, M.D., Haifaa Abdulhaq, M.D., Jean Goy, RN, Lisa Wilt, RN, Rich Wonder, RN, John Lister, M.D

Blood (2008) 112 (11): 4041.

https://doi.org/10.1182/blood.V112.11.4041.4041

Published: 2008

Journal Articles

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Haifaa Abdulhaq, MD, Bushra Haq, MD, James M. Rossetti, DO, Richard K. Shadduck, MD, Entezam Sahovic, MD, Dijana Christianson, DO, John Lister, MD

Blood (2008) 112 (11): 5072.

https://doi.org/10.1182/blood.V112.11.5072.5072

Published: 2008

NARROW

Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma

Trends in Diffuse Large B-Cell Lymphoma Mortality in the United States: A Comprehensive Review from 2000 to 2020

Disparities in Genetic Profiles, Risk Stratification and Outcomes in Adults with Acute Myeloid Leukemia Comparing Patients of Hispanic and Non-Hispanic Ethnicity in Central California

Realmind: A Prospective and Retrospective Study to Characterize Real-World Use of Tafasitamab Plus Lenalidomide in US Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, with a Focus on Patients from Minority Groups

Optimizing Acute Sickle Cell Care at Community Health Partners Medical Center

OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators

Impact of Timing of Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity

Avoiding Daratumumab Interference with Blood Typing

Characteristics and Outcomes of Multiple Myeloma in Hispanic Versus Non-Hispanic Patients in Central California

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Ethnic Variation in Hospitalized COVID-19 Patients and Correlation with Coagulopathy, Thrombosis, Prognosis and 30 Day Mortality Outcomes in California's Central Valley

Clinicopathologic Characteristic and Natural History of Patients with Non Hereditary, Non Polycythemia Vera (NH/NPV) Persistent Polycythemia

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin

Using Targeted RNA Next Generation Sequencing and Differential Expression to Compare Primary Central Nervous System Lymphoma with CD+ DLBCL, Nodal DLBCL and EBV+ DLBCL

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia.

Azacitidine in the Treatment of Elderly Patients with Acute Myelogenous Leukemia

Activity of Azacitidine (AZA) in Chronic Myelomonocytic Leukemeia (CMML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only